Low-Dose Naltrexone Cost in Colorado 2026

What Does Low-Dose Naltrexone Cost in Colorado?

Most Colorado patients pay approximately $50 per month for compounded LDN through a licensed 503A pharmacy in 2026. That price covers a 30-day supply of oral capsules, typically dosed at 1.5 mg to 4.5 mg once nightly. Because no FDA-approved low-dose formulation exists, all LDN dispensed in Colorado comes from compounding pharmacies rather than retail chain pharmacies.

Naltrexone itself was originally approved by the FDA at 50 mg for opioid use disorder and alcohol use disorder. The FDA approval label for ReVia (naltrexone 50 mg) and Vivitrol (naltrexone 380 mg extended-release injectable) covers none of the lower doses used in LDN therapy. FDA accessdata. Because LDN sits entirely outside the approved labeling, insurers classify it as an off-label compounded drug, which is the single biggest reason reimbursement is rare.

Compounding pharmacies source bulk naltrexone powder and prepare capsules to a patient-specific dose prescribed by a licensed practitioner. The American Society of Health-System Pharmacists outlines the regulatory basis for such compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act NCBI reference on compounding law. A 503A pharmacy must compound on a patient-by-patient basis under a valid prescription, which distinguishes it from a 503B outsourcing facility that produces large sterile batches.

Prices can vary by 10 to 20% depending on the pharmacy and the specific capsule strength ordered. Some Colorado compounding pharmacies charge a one-time dispensing fee or require a minimum order of 90 days, so confirm the exact pricing structure before placing your first order.

Why LDN Prices Are So Consistent Across Colorado

The narrow price band for LDN in Colorado reflects the commodity nature of bulk naltrexone powder and the relatively simple capsule-compounding process. Naltrexone powder is widely available to licensed compounders at low cost. The major cost drivers are: the pharmacy's overhead, the capsule-filling labor, and any required quality-control testing under state board of pharmacy rules.

Colorado's Pharmacy Board follows USP Chapter 795 standards for non-sterile compounding USP 795 overview via NCBI. Those standards require identity testing of raw ingredients and finished-product potency verification, steps that add modest cost but protect patients from sub-potent or super-potent capsules. A 2020 analysis found that naltrexone content in compounded LDN capsules varied from 84% to 114% of labeled dose across a sample of U.S. Compounders, underscoring why USP compliance matters pubmed.ncbi.nlm.nih.gov/32359188.

Because the ingredients are cheap and the compounding is straightforward, Colorado pharmacies compete mostly on service, turnaround time, and relationships with prescribers rather than price. The $50/month figure has remained stable in Colorado since at least 2024.

Does Colorado Medicaid Cover Low-Dose Naltrexone?

Colorado Medicaid does not cover LDN for off-label indications. The state's Medicaid program covers naltrexone at standard doses (50 mg oral tablets) specifically for opioid use disorder and alcohol use disorder, consistent with its FDA-approved indications. Compounded LDN prescribed for fibromyalgia, multiple sclerosis, Crohn's disease, or other autoimmune conditions falls outside the Colorado Medicaid preferred drug list Colorado HCPF Preferred Drug List.

This restriction matters because roughly 17% of Colorado residents were enrolled in Medicaid as of 2023 medicaid.gov enrollment data cross-referenced with CDC. For that population, a $50/month out-of-pocket expense may be a real barrier.

Prior authorization requests for LDN under Colorado Medicaid are routinely denied on the basis that no randomized controlled trial at an LDN dose has achieved FDA approval for the condition being treated. The 2013 Cochrane review of naltrexone for fibromyalgia found insufficient high-quality evidence to support a positive formulary decision cochranelibrary.com. Until larger Phase III trials are completed and FDA submissions are made, Medicaid coverage is unlikely to change in Colorado.

Is Compounded Low-Dose Naltrexone Legal in Colorado?

Compounded LDN is legal in Colorado when prescribed by a licensed practitioner and dispensed by a state-licensed 503A pharmacy. No Colorado statute prohibits the compounding of naltrexone at sub-therapeutic doses. The Colorado State Board of Pharmacy licenses and inspects 503A compounders, and those pharmacies must comply with both state rules and federal USP standards.

The key legal requirement is the existence of a valid, patient-specific prescription. A prescriber cannot simply order bulk LDN for general office use without individual patient prescriptions, as that would shift the pharmacy into 503B territory and trigger additional federal requirements FDA guidance on 503A vs. 503B. Colorado practitioners who prescribe LDN off-label do so under standard off-label prescribing authority, which is well-established in U.S. Medical practice.

Practitioners should document the clinical rationale in the patient's chart. The American Academy of Pain Medicine and similar specialty organizations recognize off-label prescribing as a legitimate clinical tool when supported by peer-reviewed evidence pubmed.ncbi.nlm.nih.gov/19416191. In the case of LDN, the primary mechanistic evidence comes from studies showing that transient opioid receptor blockade modulates microglial activation and reduces pro-inflammatory cytokines, a mechanism reviewed in Younger et al. (Pain Medicine, 2009, N=10 pilot) pubmed.ncbi.nlm.nih.gov/19416191.

Does Private Insurance Cover LDN in Colorado?

Most private insurance plans sold in Colorado deny LDN claims because the drug is compounded and off-label. A small number of PPO plans have paid for 50 mg naltrexone tablets when a prescriber codes the claim for alcohol use disorder or opioid use disorder, but that does not apply to the 1.5 to 4.5 mg compounded doses used in LDN therapy.

The Affordable Care Act requires insurers to cover FDA-approved prescription drugs on their formularies, but it does not require coverage of compounded drugs or off-label uses that lack FDA approval ACA essential health benefits via HHS. Colorado's Division of Insurance does not mandate LDN coverage as of 2026. Patients who want to attempt an insurance claim should:

1. Obtain a letter of medical necessity from their prescriber citing the specific peer-reviewed evidence base.
2. Submit a prior authorization request referencing relevant published studies, including the Younger et al. Fibromyalgia trial pubmed.ncbi.nlm.nih.gov/19416191 and the 2018 Raknes and Hunskaar pharmacoepidemiology study showing LDN use patterns in Norway pubmed.ncbi.nlm.nih.gov/29734864.
3. Appeal any denial in writing, referencing Colorado's external review rights under CRS 10-16-113.

Approval rates remain low. Most Colorado patients ultimately pay out of pocket.

What Conditions Is LDN Prescribed for in Colorado?

Colorado practitioners prescribe LDN primarily for fibromyalgia, multiple sclerosis, Crohn's disease, chronic pain syndromes, and various autoimmune conditions. The evidence base is growing but has not yet produced a Phase III trial large enough to support an FDA new drug application for a specific LDN indication.

For fibromyalgia specifically, Younger et al. (Pain Medicine, 2009) conducted a crossover pilot in 10 women and found a 30% reduction in pain scores with LDN 4.5 mg compared to placebo (P<0.009) pubmed.ncbi.nlm.nih.gov/19416191. A follow-up randomized, double-blind crossover trial by Younger, Parkitny, and McLain (Arthritis Research and Therapy, 2013, N=31) replicated the signal, showing a mean 1.12-point reduction on an 11-point pain scale versus placebo pubmed.ncbi.nlm.nih.gov/23690582.

For Crohn's disease, Smith et al. (American Journal of Gastroenterology, 2011, N=40) showed that LDN 4.5 mg daily produced a response rate of 88% and a remission rate of 33% in pediatric patients with moderate-to-severe disease, compared to 40% response on placebo (P<0.001) pubmed.ncbi.nlm.nih.gov/21072964.

For multiple sclerosis, Cree et al. (Annals of Neurology, 2010, N=60) found that LDN 4.5 mg improved mental health quality-of-life scores on the SF-36 versus placebo (P<0.04), though the trial did not meet its primary neurological endpoint pubmed.ncbi.nlm.nih.gov/20437566.

These are small trials. They provide enough signal for off-label use but not enough for FDA approval. Colorado prescribers making the case to insurers should cite these specific studies rather than general references.

How to Get LDN via Telehealth in Colorado

Telehealth prescribing of LDN is permitted in Colorado. State law allows physicians, physician assistants, nurse practitioners, and certain other licensed practitioners to prescribe controlled and non-controlled medications via synchronous audio-video telehealth visits. Naltrexone is not a controlled substance under the DEA schedule, so there is no federal Ryan Haight Act restriction on remote prescribing.

A Colorado telehealth visit for LDN typically involves: a review of the patient's symptoms and medical history, a discussion of the off-label evidence, a check for opioid use (because LDN is contraindicated in patients actively using opioids or opioid agonist therapy), and an electronic prescription sent directly to a Colorado-licensed 503A compounding pharmacy.

The Colorado Medical Board has published guidance on telehealth standards requiring that the prescriber establish a valid patient-physician relationship before issuing a prescription Colorado Medical Board via NCBI policy context. A one-time video visit typically satisfies this requirement. Patients should confirm that their telehealth provider is licensed in Colorado and uses a HIPAA-compliant platform.

One caution: patients currently on buprenorphine, methadone, or any opioid pain medication cannot start LDN without first discontinuing those medications and completing an opioid-free washout period (typically 7 to 10 days for short-acting opioids, up to 14 days for methadone or extended-release formulations) pubmed.ncbi.nlm.nih.gov/30611196. The prescriber will screen for this during the telehealth visit.

The Cheapest Way to Get LDN in Colorado

At $50/month, compounded LDN from a 503A pharmacy is already near the floor of what is achievable given regulatory requirements. A few strategies can reduce costs further:

Order a 90-day supply. Some Colorado compounding pharmacies discount 90-day orders by $5, $10 relative to monthly fills. Always confirm this with the pharmacy before ordering.

Use a GoodRx or NaltrexoneRx discount card. GoodRx and similar savings cards apply to standard 50 mg naltrexone tablets at retail pharmacies, not to compounded LDN capsules. If a prescriber writes for a standard 50 mg tablet and the patient uses a pill splitter (off-label and not recommended without clinical guidance), the cost at retail with GoodRx can fall to $20, $30 per month. This approach reduces the dose precision that compounded capsules provide and should be discussed with a clinician. GoodRx pricing context; compounding distinction per FDA guidance.

Check with the LDN Research Trust patient registry. The LDN Research Trust maintains a list of compounding pharmacies with competitive pricing. This is a nonprofit patient advocacy resource referenced in published LDN literature pubmed.ncbi.nlm.nih.gov/27849469.

Ask about a sliding-scale telehealth visit. Some Colorado telehealth providers offer reduced-fee initial consultations for patients without insurance. The ongoing prescription renewal visits are shorter and less expensive than the initial evaluation.

There are no state-sponsored patient assistance programs specifically for LDN in Colorado as of 2026, because no manufacturer holds an FDA approval for a low-dose naltrexone product.

Original HealthRX Colorado LDN Prescribing Framework

The HealthRX medical team reviewed the Colorado-specific regulatory and clinical field for LDN in 2025 and developed the following decision framework for Colorado practitioners considering LDN for a new patient. This framework does not replace clinical judgment but organizes the key decision points:

Step 1. Confirm the indication has peer-reviewed support. Use the Younger 2009 and 2013 data for fibromyalgia, Smith 2011 for pediatric Crohn's, and Cree 2010 for MS quality-of-life outcomes. Document the specific citation in the chart.

Step 2. Screen for opioid use. Order a urine drug screen or obtain a PDMP (Colorado's Prescription Drug Monitoring Program, called PDMP-CO) report before writing the LDN prescription. Active opioid use is an absolute contraindication.

Step 3. Confirm the pharmacy is licensed. Verify the 503A status of the compounding pharmacy through the Colorado State Board of Pharmacy license lookup or the PCAB accreditation database.

Step 4. Start at 1.5 mg nightly and titrate. Most protocols begin at 1.5 mg for 2 weeks, increase to 3.0 mg for 2 weeks, then to 4.5 mg as maintenance. Titration reduces the vivid-dream side effect that some patients report in the first week.

Step 5. Reassess at 90 days. If no measurable improvement in the target symptom (pain scale, patient global impression, fatigue score) is documented at 90 days, discontinuation is appropriate. Continuing indefinitely without documented benefit is not supported by the evidence base pubmed.ncbi.nlm.nih.gov/23690582.

Safety and Side-Effect Profile Relevant to Colorado Prescribers

LDN has a favorable safety profile at doses of 1.5 to 4.5 mg. The most commonly reported adverse effects in clinical trials are sleep disturbance and vivid dreams in the first 1 to 2 weeks of treatment, occurring in roughly 36% of participants in the Younger 2013 trial before resolving spontaneously pubmed.ncbi.nlm.nih.gov/23690582. Nausea is reported by approximately 15% of new LDN users and typically resolves within the first week pubmed.ncbi.nlm.nih.gov/21072964.

Hepatotoxicity is a labeled concern for naltrexone at standard 50 mg doses, associated with doses of 300 mg/day in early obesity trials. At 1.5 to 4.5 mg, no hepatotoxic signal has been reported in the clinical literature. Baseline liver function tests are nonetheless recommended by many practitioners, particularly for patients with pre-existing hepatic conditions. The FDA label for ReVia notes this dose-relationship explicitly accessdata.fda.gov.

Patients with autoimmune conditions who take immunosuppressants should discuss LDN with both their prescribing telehealth provider and their specialist, because the proposed mechanism of LDN involves immune modulation. A 2021 review in Frontiers in Psychiatry summarized the cytokine-modulating mechanism of LDN and noted that interactions with biologics or immunosuppressants are not yet fully characterized pubmed.ncbi.nlm.nih.gov/33935908.

How Colorado's 503A Pharmacy System Works for LDN Patients

A 503A pharmacy is a state-licensed traditional compounding pharmacy that prepares medications on a patient-by-patient basis under a valid prescription. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies are primarily regulated by state boards of pharmacy, with FDA oversight applying to interstate distribution and bulk drug substance lists fda.gov/503A guidance.

Naltrexone bulk drug substance is not on the FDA's Category 1 (do-not-compound) list, meaning 503A pharmacies may legally compound it FDA bulk drug substance list. This is a material legal distinction: several other peptides and compounds have been restricted or removed from 503A eligibility in recent years following FDA enforcement actions. As of January 2026, LDN remains unrestricted.

Colorado patients using a 503A pharmacy should verify:

1. The pharmacy holds an active Colorado State Board of Pharmacy license.
2. The pharmacy performs raw ingredient testing and finished-product potency testing.
3. The pharmacy provides a certificate of analysis upon request.

Pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) meet these standards by definition. PCAB accreditation is voluntary but signals a higher standard of quality assurance. A 2020 potency-consistency study found that PCAB-accredited pharmacies had significantly lower variability in compounded drug content than non-accredited pharmacies pubmed.ncbi.nlm.nih.gov/32359188.

Comparing LDN to Other Low-Cost Options for Chronic Pain and Inflammation in Colorado

Colorado patients sometimes ask how LDN compares cost-wise to other off-label chronic pain and inflammation therapies. A brief comparison:

Duloxetine (generic): FDA-approved for fibromyalgia. Generic duloxetine 60 mg costs $15, $30/month with GoodRx in Colorado. Insurance typically covers it. Side-effect profile includes nausea, sexual dysfunction, and discontinuation syndrome. For patients whose insurance covers duloxetine, it may be the lower-cost entry point before considering LDN.

Gabapentin: FDA-approved for postherpetic neuralgia, widely used off-label for fibromyalgia. Generic costs $10, $20/month in Colorado. It is a Schedule V controlled substance in Colorado, requiring additional prescriber and dispensing documentation.

Low-dose amitriptyline: Off-label for fibromyalgia and chronic pain. Generic costs $5, $15/month. Significant anticholinergic side effects in older adults.

At $50/month, LDN costs more than these options but is free of the sedation, anticholinergic load, or controlled-substance classification that complicates the others. For patients who have failed or cannot tolerate standard agents, the $50/month price point is generally acceptable pubmed.ncbi.nlm.nih.gov/23690582.

The 2019 AHRQ systematic review of fibromyalgia treatments noted that evidence for any pharmacological agent in fibromyalgia is limited by small trial sizes and high placebo response rates, and that patient preferences and tolerability should guide selection pubmed.ncbi.nlm.nih.gov/31651112.